Lucid Diagnostics Shares Fall After Pricing of Public Stock Offering

Dow Jones

09/10

By Freddy Sebastian

Shares of Lucid Diagnostics fell after its secondary offering of common shares priced.

Its stock slid 17.3% to $1.05 in premarket trading on Wednesday.

The cancer-prevention medical diagnostics company said its underwritten public offering of 25 million shares was priced at $1 apiece.

Lucid also said it granted underwriters a 30-day option to purchase up to an additional 3.75 million common shares at the public offering price, excluding underwriting discounts and commissions.

The offering is expected to close on Thursday.

The company, which is a unit of PAVmed Inc., said it would use the gross proceeds of $25 million for working capital and general corporate purposes.

Write to Freddy Sebastian at freddy.sebastian@wsj.com

(END) Dow Jones Newswires

September 10, 2025 09:00 ET (13:00 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2566601552"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2566601552\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2566601552?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-10 21:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2566601552","market":"us","top_or_hot":-1,"title":"Lucid Diagnostics Shares Fall After Pricing of Public Stock Offering","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Freddy Sebastian \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/LUCD\">Lucid Diagnostics</a> fell after its secondary offering of common shares priced. \n</p>\n<p>\n  Its stock slid 17.3% to $1.05 in premarket trading on Wednesday. \n</p>\n<p>\n  The cancer-prevention medical diagnostics company said its underwritten public offering of 25 million shares was priced at $1 apiece. \n</p>\n<p>\n  <a href=\"https://laohu8.com/S/LCID\">Lucid</a> also said it granted underwriters a 30-day option to purchase up to an additional 3.75 million common shares at the public offering price, excluding underwriting discounts and commissions. \n</p>\n<p>\n  The offering is expected to close on Thursday. \n</p>\n<p>\n  The company, which is a unit of <a href=\"https://laohu8.com/S/PAVM\">PAVmed Inc.</a>, said it would use the gross proceeds of $25 million for working capital and general corporate purposes. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Freddy Sebastian at freddy.sebastian@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  September 10, 2025 09:00 ET (13:00 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lucid Diagnostics Shares Fall After Pricing of Public Stock Offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLucid Diagnostics Shares Fall After Pricing of Public Stock Offering\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-09-10 21:00</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Freddy Sebastian \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/LUCD\">Lucid Diagnostics</a> fell after its secondary offering of common shares priced. \n</p>\n<p>\n  Its stock slid 17.3% to $1.05 in premarket trading on Wednesday. \n</p>\n<p>\n  The cancer-prevention medical diagnostics company said its underwritten public offering of 25 million shares was priced at $1 apiece. \n</p>\n<p>\n  <a href=\"https://laohu8.com/S/LCID\">Lucid</a> also said it granted underwriters a 30-day option to purchase up to an additional 3.75 million common shares at the public offering price, excluding underwriting discounts and commissions. \n</p>\n<p>\n  The offering is expected to close on Thursday. \n</p>\n<p>\n  The company, which is a unit of <a href=\"https://laohu8.com/S/PAVM\">PAVmed Inc.</a>, said it would use the gross proceeds of $25 million for working capital and general corporate purposes. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Freddy Sebastian at freddy.sebastian@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  September 10, 2025 09:00 ET (13:00 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2566601552","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2566601552","pubTimestamp":1757509200,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Lucid Diagnostics fell after its secondary offering of common shares priced.Its stock slid 17.3% to $1.05 in premarket trading on Wednesday.The cancer-prevention medical diagnostics company said its underwritten public offering of 25 million shares was priced at $1 apiece.Lucid also said it granted underwriters a 30-day option to purchase up to an additional 3.75 million common shares at the public offering price, excluding underwriting discounts and commissions.The offering is expected to close on Thursday.The company, which is a unit of PAVmed Inc., said it would use the gross proceeds of $25 million for working capital and general corporate purposes.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","BK4555":"新能源车","LUCD":"LUCID DIAGNOSTICS INC.","BK4596":"哈里斯概念","BK4551":"寇图资本持仓","BK4099":"汽车制造商"},"translate_title":"Lucid Diagnostics股价在公开股票发行定价后下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LUCD":0.9},"content_text":"By Freddy Sebastian \n\n\n \n\n\n  Shares of Lucid Diagnostics fell after its secondary offering of common shares priced. \n\n\n  Its stock slid 17.3% to $1.05 in premarket trading on Wednesday. \n\n\n  The cancer-prevention medical diagnostics company said its underwritten public offering of 25 million shares was priced at $1 apiece. \n\n\nLucid also said it granted underwriters a 30-day option to purchase up to an additional 3.75 million common shares at the public offering price, excluding underwriting discounts and commissions. \n\n\n  The offering is expected to close on Thursday. \n\n\n  The company, which is a unit of PAVmed Inc., said it would use the gross proceeds of $25 million for working capital and general corporate purposes. \n\n\n \n\n\n  Write to Freddy Sebastian at freddy.sebastian@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 10, 2025 09:00 ET (13:00 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}